GlassScriptPhysician profile
Michael Brennan Royalty
NPI 1083740377
$1,418.72
in general payments reported to CMS, 2019-2025
19 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $162 · 2022: $11.40 · 2023: $245 · 2024: $289 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $167.91 | 2019-2025 | Airsupra |
| Abbvie INC. | $165.26 | 2023-2025 | Ubrelvy |
| Amgen INC. | $148.30 | 2019-2024 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $141.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $134.16 | 2019-2024 | |
| Lilly USA, LLC | $104.37 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $92.69 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.61 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $88.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $45.72 | 2023-2024 | Myrbetriq, Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.60 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.72 | 2020-2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $34.83 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $32.69 | 2024-2025 | |
| Amarin Pharma, INC. | $30.10 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $23.88 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $15.67 | 2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $13.79 | 2020 | |
| Merck Sharp & Dohme LLC | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Royalty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.